-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, CSPC has entered the administrative examination and approval stage with the imitation of the 4 types of apixaban tablets, and is expected to be approved for listing in the near future
Apixaban is a highly selective direct factor Xa inhibitor jointly developed by Bristol-Myers Squibb and Pfizer.
Bristol-Myers Squibb Eliquis global sales (unit: million dollars)
Source: Mynet.
Apixaban was first approved for listing in China in 2013, and the previous market sales have been bleak, and the market scale has grown by leaps and bounds in recent years
Apixaban tablets have been included in the third batch of centralized procurement.
As a popular product, there are more than 30 companies with Apixaban tablets.
Data source: Mi Neiwang database